Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

• Published in: European heart journal Vol. 45; no. 14; pp. 1224 - 1240
• Main Authors: Sayour, Nabil V, Paál, Ágnes M, Ameri, Pietro, Meijers, Wouter C, Minotti, Giorgio, Andreadou, Ioanna, Lombardo, Antonella, Camilli, Massimiliano, Drexel, Heinz, Grove, Erik Lerkevang, Dan, Gheorghe Andrei, Ivanescu, Andreea, Semb, Anne Grete, Savarese, Gianluigi, Dobrev, Dobromir, Crea, Filippo, Kaski, Juan-Carlos, de Boer, Rudolf A, Ferdinandy, Péter, Varga, Zoltán V
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 07.04.2024
• Subjects: Heart Failure - drug therapy; Humans; Medicin och hälsovetenskap; Neoplasms - epidemiology; State of the Art Review; Heart failure; Mineralocorticoid Receptor antagonist; Beta-blocker; Cardio-oncology; Angiotensin-converting enzyme inhibitor; Sodium-glucose cotransporter 2 inhibitor; Angiotensin receptor blocker; Angiotensin receptor-neprilysin inhibitor; Cancer
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehae105

Abstract Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided. Graphical Abstract Graphical abstract The risk factors and pathophysiological pathways of both heart failure and cancer are common. The discipline of cardio-oncology investigates how heart failure and cancer progression are connected: on one hand, the cardiac effects of anti-cancer medications or cancer-derived metabolic byproducts are investigated, whereas on the other hand, the possible effects of heart failure on cancer progression are examined, such as those mediated by maladaptive neuroendocrine activation and factors secreted from the failing heart. Nevertheless, there is a lack of systematic knowledge on how heart failure pharmacotherapies affect new-onset cancer incidence or prevalent cancer outcomes, and whether these effects are mediated through the improvement in cardiac functions. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; MRA, mineralocorticoid receptor antagonist; SGLT2I, sodium-glucose cotransporter 2 inhibitor.